Anonymized outcomes from real studies across our sites. Sponsor names and study identifiers stay confidential, always; the numbers speak for themselves. For live operational metrics, see the performance board.
In a Phase 2 study for angiokeratoma, a condition affecting 50,000+ people in the U.S. with no FDA-approved therapy, a Stryde site enrolled and dosed the first patient anywhere in the world. Rare-disease readiness is a speed story: pre-tagged panels and startup discipline made the difference.
The story →In a global lupus study where only three patients had been randomized anywhere, Stryde delivered one of them. Lupus randomization is among the hardest milestones in clinical research; execution at the coordinator and recruitment level is what gets a site there.
The story →First patient randomized in a trial of a new injection-based skin cancer treatment, pointing toward a less invasive option for patients cycling through repeated procedures. Sourced from the practice's own panel, no recruitment campaign required.
The story →Preliminary feasibility from real tagged patient counts in 48 business hours, guaranteed and tracked.